FASTIN
LOE ApproachingNDAORALCAPSULE
Approved
Aug 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
2/8 — Basic
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FASTIN is an oral small-molecule capsule approved in 1973 by GSK with an extraordinarily broad indication portfolio spanning oncology (NSCLC, HNSCC, pancreatic, colorectal, breast, sarcoma), metabolic/endocrine disorders (T2D, obesity, hypertension, dyslipidemia), autoimmune conditions (RA, UC), infectious diseases (aspergillosis, HIV), neuropsychiatric conditions (Alzheimer's, depression, marijuana use disorder), and rare genetic disease (CPT1A deficiency). The mechanism of action and pharmacologic class are unknown, suggesting either legacy data gaps or a multi-target profile not fully characterized in modern literature.
LOE Approaching
Product is in late lifecycle stage with moderate competitive pressure (30/100), signaling a contracting or defensive team structure focused on retention and compliance rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus
Started Jan 2026
40 enrolled
Diabetes Mellitus, Type 2OverweightObesity
A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus
Started Dec 2025
20 enrolled
Type 2 Diabetes Mellitus (T2DM)
Pharmacokinetics and Safety Profiles of DA-1229_01 in Healthy Subjects at Fasting State
Started Dec 2025
42 enrolled
Healthy
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
Started Nov 2025
75 enrolled
Obesity
Comparison of DW-1021 and Separate Doses of Pelubi CR and Zytram CR Under Fasting Conditions
Started Sep 2025
14 enrolled
Healthy Volunteer
Worked on FASTIN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.